|
Dual-Action Inhibition Strategy for KRAS and LKB1 Mutant NSCLC
NU 2023-113
INVENTORS
Lillian Eichner (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
Reuben Shaw (Salk Institute)
SHORT DESCRIPTION
A dual drug combination to target KRAS and LKB1 mutant non–small cell lung cancer that results in superior efficacy by enhancing T cell recruitment and reducing tumor burden.
BACKGROUND
Lung...
Published: 4/29/2026
|
Updated: 4/29/2026
|
Inventor(s): Reuben Shaw
Keywords(s): Cancer/Oncology, Lung cancer, Repurposed Drugs, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|